Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen

Journal of Immunology

Volumn 156, Issue 1, 1996, Pages 224-231

  Chen, Pauline W ^a   Wang, Michael ^b   Bronte, Vincenzo ^a   Zhai, Yifan ^a   Rosenberg, Steven A ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; INTERLEUKIN 2; N METHYL N NITROSOURETHAN; RECOMBINANT INTERLEUKIN 2; TUMOR ANTIGEN;

ADENOVIRUS; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR IMMUNITY; VIRUS RECOMBINANT; VIRUS TITRATION;

ADENOCARCINOMA; ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; IMMUNIZATION, SECONDARY; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 0030047315     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Rosenberg, S A , B. S. Packard, P. M Aebersold, D. Solomon, S L. Topalian. S. T. Toy, P. Simon, M. T. Lotze, J C Yang, C. A Seipp, C Simpson, C. Carter, S. Bock, D. Schwartzentruber, J. P. Wei, and D E. White. 1988 Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma Preliminary report N. Engl J. Med 319:1676
2. Rosenberg, S. A., J R. Yannelli, J. C Yang, S. L. Topalian, D. J. Schwartzentruber, J S. Weber, D. R. Parkinson, C A Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86:1159.
3. Alexander, R B., and S. A Rosenberg. 1990. Long term survival of adoptively-transferred tumor infiltrating lymphocytes in mice. J. Immunol. 145:1615
4. Boon, T., J. Cerottini, B Van den Eynde, P. van der Bruggen, and A. Van Pel 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev Immunol 12 337
5. Brichard, V., A. Van Pel, T. Wolfel, C. Wolfel, E. De Plaen, B. Lethe, P Coulie, and T Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178 489.
6. Cox, A. L., J Skipper, Y. Chen, R. A. Henderson, T. L Darrow, J Shabanowitz, V H. Engelhard, D. F. Hunt, and C. L. Slingluff, Jr. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716.
7. Houghton, A. N. 1994. Cancer antigens: immune recognition of self and altered self. J Exp Med 180:1.
8. Pardoll, D. M. 1994 Tumour antigens A new look for the 1990s. Nature 369 357.
9. Kawakami, Y , S Eliyahu, C. H Delgado, P. F. Robbins, L Rivoltini, S L. Topalian, T. Miki, and S. A Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad Sci. USA 91:3515.
10. Kawakami, Y., S. Eliyahu, C H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg. 1994 Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl Acad. Sci USA 91:6458
11. Robbins, P. F., M. El-Gamil, Y. Kawakami, E. Stevens, J. R. Yannelli, and S A Rosenberg. 1994. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy [published erratum appears in Cancer Res 1994 Jul 15;54(14).3952]. Cancer Res. 54.3124.
12. Wang, R. F., P. F. Robbins, Y. Kawakami, X. Q. Kang, and S. A. Rosenberg. 1995. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes [published erratum appears in J Exp Med 1995 Mar 1.181(3).1261]. J. Exp Med. 181:799.
13. Wang, M , V Bronte, P W. Chen, L. Gritz, D. Panicali, S A. Rosenberg, and N. P. Restifo. 1995 Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol 154:4685
14. Bronte, V., K Tsung, J B. Rao, P. W. Chen, M. Wang, S. A. Rosenberg, and N P. Restifo. 1995. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154. 5282
15. Top, F H , Jr. 1975 Control of adenovirus acute respiratory disease in U.S. Army trainees. Yale J Biol. Med. 48:185.
16. Chaloner-Larsson, G., G. Contreras, J Furesz, D. W. Boucher, D Krepps, G. R. Humphreys, and S. M. Mohanna. 1986 Immunization of Canadian Armed Forces personnel with live types 4 and 7 adenovirus vaccines Can. J Public Health 77:367.
17. Rich, D. P . L. A Couture, L. M. Cardoza, V. M. Guiggio, D Armentano, P. C. Espino, K. Hehir, M J. Welsh, A E. Smith, and R. J Gregory. 1993. Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Hum. Gene Ther 4:461
18. Kozarsky, K F., and J. M. Wilson. 1993 Gene therapy: adenovirus vectors. Curr Opin. Genet Dev. 3:499.
19. Schneider, M. D., and B. A. French. 1993. The advent of adenovirus Gene therapy for cardiovascular disease Circulation 88 1937
20. Cristiano, R J , L C. Smith, M A Kay, B. R. Brinkley, and S L. Woo. 1993 Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc Nad Acad. Sci. USA 90 11548
21. Chen, S J , J. M Wilson, and D. W Muller 1994. Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. Circulation 89:1922.
22. Zabner, J., D. M. Petersen, A P. Puga, S. M Graham, L. A. Couture, L. D. Keyes, M. J. Lukason, J A. St. George, R. J. Gregory, and A E. Smith 1994. Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nat. Genet. 6:75.
23. Zabner, J., L. A. Couture, R J. Gregory, S. M. Graham, A. E. Smith, and M. J. Welsh. 1993. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect m nasal epithelia of patients with cystic fibrosis. Cell 75:207.
24. Mastrangeli, A., C. Danel, M A. Rosenfeld, L. Stratford-Perricaudet, M. Perricaudet, A. Paviram, J. P Lecocq, and R G Crystal 1993 Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer J. Clin. Invest 91:225.
25. Crystal, R G., N G. McElvaney, M A. Rosenfeld, C. S. Chu, A. Mastrangeli, J. G. Hay, S. L Brody, H. A. Jaffe, N T. Eissa, and C. Danel. 1994. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis [see comments]. Nat. Genet. 8:42
26. Yang, Y., F. A. Nunes, K. Berenesi, E. E. Furth, E Gonezol, and J M Wilson. 1994 Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci USA 91:4407.
27. Engelhardt, J. F., X. Ye, B. Doranz, and J. M. Wilson 1994. Ablation of E2A m recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad. Sci. USA 91:6196.
28. Quantin, B , L. D Perricaudet, S. Tajbakhsh, and J L Mandel 1992. Adenovirus as an expression vector in muscle cells in vivo. Proc Natl. Acad. Sci USA 89.2581.
29. Bessereau, J L., L. D. Stratford-Perricaudet, J. Piette, C. Le Poupon, and J P. Changeux. 1994. In vivo and in vitro analysis of electrical activity-dependent expression of muscle acetylcholine receptor genes using adenovirus Proc Natl. Acad. Sci. USA 91:1304
30. Gallichan, W S., D C. Johnson, F. L. Graham, and K L. Rosenthal. 1993. Mucosal immunity and protection after intranasal immunization with recombinam adenovirus expressing herpes simplex virus glycoprotein B. J. Infect. Dis. 168.622
31. Huard, J , H. Lochmuller, G. Acsadi, A. Jani, B Massie, and O Karpati 1995. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 2:107.
32. Brattain, M. G , J Strobel-Stevens, D. Fine, M. Webb, and A. M. Sarrif 1980. Establishment of mouse colonie carcinoma cell lines with different metastatic properties. Cancer Res. 40:2142.
33. Boshart, M., F. Weber, G Jahn, K Dorsch-Hasler, B. Fleckenstein, and W. Schaffner. 1985. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus Cell 41:521.
34. Hwu, P., G. E. Shafer, J. Treisman, D. G. Schindler, G. Gross, R. Cowherd, S. A. Rosenberg, and Z. Eshhar. 1993. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J. Exp. med. 178:361.
35. Zhai, Y., J. C. Yang, Y Kawakami, P. Spiess, C Wadsworth, L. M Cardoza, L. A. Couture, A. E. Smith, and S. A Rosenberg. 1996. Antigen-specific tumor vaccines, development and characterization of recombinant adenoviruses encoding MART or gp100 for cancer therapy. J. Immunol. In press
36. Lynn, D E 1992. A BASIC computer program for analyzing endpoint assays Biotechniques 12:880.
37. Gavin, M. A., M. J. Gilbert, S. R. Riddell, P D. Greenberg, and M. J. Bevan. 1993 Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. J. Immunol. 151:3971.
38. Restifo, N. P., F. Esquivel, Y. Kawakami, J. W. Yewdell, J. J. Mule, S. A. Rosenberg, and J. R. Bennink. 1993. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177:265.
39. Mule, J J., J. C. Yang, R. Lafreniere, S. Shu, and S. A Rosenberg. 1987. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J. Immunol. 139.285.
40. Greenberg, P. D. 1991. Adoptive T cell therapy of tumors' mechanisms operative in the recognition and elimination of tumor cells Adv Immunol. 49.281
41. Chengalvala, M., M. D. Lubeck, A. R. Davis, S. Mizutani, K. Molnar-Kimber, J. Morin, and P. P. Hung 1991. Evaluation of adenovirus type 4 and type 7 recombinant hepatitis B vaccines in dogs. Vaccine 9:485.
42. Ragot, T , S. Finerty, P E. Watkins, M Perricaudet, and A J. Morgan. 1993. Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin. J. Gen Virol. 74:501.
43. Berencsi, K., R F Rando, C. deTaisne, E Paoletti, S A. Plotkin, and E. Gonezol. 1993. Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB. J. Gen. Virol. 74-2507
44. Baxby, D., and E. Paoletti 1992. Potential use of non-replicating vectors as recombinant vaccines. Vaccine 10:8.
45. Redfield, R R , D. C. Wright, W. D. James, T. S. Jones, C. Brown, and D S Burke. 1987 Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med. 316.673.
46. Yang, Y., Q. Li, H. C. G. Ertl, and J. M. Wilson 1995 Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol 69:2004.